Therapeutic charge engineered variants of lysozyme and methods for using same to treat infections
US9950041B2 · kind B2 · utility
0Cited by
1References
1Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 6, 2015 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | Dec 6, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.